---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010925"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:17:47.453921+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotech gets USAN approval for 'ateganosine' as generic name for THIO in NSCLC

## Summary
- USAN Council approved nonproprietary name 'ateganosine' for lead molecule THIO, a telomere-targeting anticancer agent.
- Naming is an essential step in FDA approval process for THIO in advanced non-small cell lung cancer (NSCLC).
- MAIA will retain THIO name for clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).
- No financial terms disclosed; no change in guidance or operations.

## SEC filing metadata
- accession: 0001493152-25-010925
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225010925/0001493152-25-010925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225010925/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010925
- JSON: https://secwatch.observer/filing/0001493152-25-010925.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.